Copenhagen, 2 September 2010 - Today, NeuroSearch A/S (NEUR) announced that the
unique in vivo pharmacological properties of pridopidine (brand name Huntexil®)
have been published online in the European Journal of Pharmacology in an
article entitled, "In vivo pharmacology of the dopaminergic stabilizer
pridopidine" (Ponten et al., Eur J Pharm 2010;644:88-95. The article will be
available in print on 10 October 2010.

Earlier this year, NeuroSearch reported clinical results from a Phase III trial
- the MermaiHD study - with pridopidine (Huntexil®) for the treatment of
Huntington's disease, a severe neurological disorder that has orphan disease
status. The results of the MermaiHD study demonstrated that pridopidine has a
unique and positive effect on motor function in patients with Huntington's
disease, including the ability to improve both voluntary and involuntary
movements, and that the drug also has a good safety profile. Additional
clinical studies are ongoing, from which NeuroSearch expects to report the
results in the coming months.

● Pridopidine is one of the first drugs in a novel class of pharmacological
agents, established by NeuroSearch and known as dopidines (previously
designated dopaminergic stabilizers), which act on the central nervous system
(CNS). Pridopidine is the first dopidine to have demonstrated clinical
efficacy.

- Dopidines act primarily at dopamine type 2 (D2) receptors, enhancing or
reducing dopamine-dependent effects according to the initial level of activity.

- These agents are able to reduce excitatory and inhibitory stress, and thus to
lead to improved behavioural performance via regulation of both hyper- and
hypoactive states in areas of the brain that receive dopamine input.

- Thus, dopidines have the potential to treat neurological and psychiatric
disorders characterized by altered dopamine transmission, including
Huntington's disease.

● In the article, Ponten et al. provide an overview of the preclinical
neurochemical and behavioural pharmacological properties of pridopidine, and
show that this agent:

- produces dose-dependent increases in striatal tissue levels of dopamine
metabolites

- produces dose-dependent increases in levels of dopamine and noradrenaline in
the prefrontal cortex

- reduces excessive movement in models of hyperactivity

- preserves spontaneous locomotor activity

● The state-dependent behaviour-stabilizing effects of pridopidine are not
explained solely by the agent's specific interaction with dopamine D2
receptors. Pridopidine also interacts with cortical noradrenaline and glutamate
systems, and therefore the unique pharmacological profile of pridopidine may be
dependent on dual actions of the agent:

- functional antagonism of subcortical dopamine transmission
- strengthening of cortical synaptic glutamate transmission

● The dopaminergic stabilizing properties of dopidines are, therefore, best
described in vivo as connectivity phenomena, dependent on cortical-subcortical
brain circuitry effects that are not revealed at the receptor level in vitro.
This putative restoration of cortical-subcortical circuitry function suggests
that dopidines have the potential to treat several neurological and psychiatric
disorders characterized by altered dopamine transmission, including
Huntington's disease

Contact persons:

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103

Dr. Nicholas Waters, CEO of NeuroSearch Sweden AB, telephone: +46 73 075 77 01

About Huntington's disease
Huntington's disease is a highly disabling, fatal and incurable genetic
disorder, which leads to damage of the nerve cells in certain areas of the
brain including the basal ganglia and the cerebral cortex. The disease is
hereditary and every child of someone with Huntington's disease has a 50%
chance of inheriting the disease.

Patients with Huntington's disease experience a wide variety of symptoms, which
typically can be grouped into three categories: motor dysfunction includes loss
of muscle co-ordination, parkinsonism, chorea, dystonia, and abnormal gait and
posture, which can markedly impair patients' daily functioning. Impaired
executive and cognitive functions lead to loss of organizational and planning
skills, and psychiatric changes, such as depression and anxiety, are typical;
manic and psychotic symptoms can also be present. The onset of symptoms is
typically around 35-45 years of age, after which patients deteriorate gradually
and have a life expectancy of 10-20 years.

Patients with Huntington's disease will eventually require full-time care, and
the therapy area has high unmet medical needs. No cure or effective treatment
is available and only a limited number of novel drugs are in development. The
prevalence of Huntington's disease is about 1: 10 000 in most western
countries, corresponding to an estimated 70 000 affected patients in North
America and Europe combined. In other parts of the world, the prevalence varies
substantially and is generally lower.

About NeuroSearch - company profile
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system
(CNS), and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel treatment of obesity.

NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery alliances with Janssen Pharmaceutica and Eli Lilly as
well as a licence collaboration with Abbott. Furthermore, NeuroSearch has
equity interests in a number of private companies in the Life Sciences
industry.